Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BBI-355,Futibatinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Taiho Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Taiho will provide futibatinib for Boundless Bio’s ongoing Phase 1/2 clinical trial, which will assess BBI-355 in combination with certain selected targeted therapies, including futibatinib, in patients with specific oncogene ampli...
Brand Name : BBI-355
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 18, 2023
Lead Product(s) : BBI-355,Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Taiho Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4. It has demostrated anti-tumour activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations...
Brand Name : Lytgobi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 04, 2023
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CHMP Issues Positive Opinion for Futibatinib for The Treatment of Adults with Cholangiocarcinoma
Details : TAS-120 (futibatinib) is an oral, potent, selective, and irreversible tyrosine kinase inhibitor of FGFR1, 2, 3 and 4 being studied as a potential treatment for patients with advanced solid tumors with FGFR1-4 genetic aberrations, including cholangiocarci...
Brand Name : TAS-120
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2023
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR. It has demonstrated anti-tumor activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations.
Brand Name : Lytgobi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 13, 2023
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4. It has demostrated anti-tumour activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations...
Brand Name : Lytgobi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 18, 2023
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Key presentations include: Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Acquired resistance to ATP-competitive and irreversible FGFR inhibitor...
Brand Name : TAS-120
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 02, 2021
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Abstracts will highlight subgroup analyses of a phase 2 study evaluating efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (i cca) harboring fgfr2 fusions/other rearrangements.
Brand Name : TAS-120
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2020
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Futibatinib,Olaparib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Taiho Oncology
Deal Size : Undisclosed
Deal Type : Funding
Details : In a phase 1 dose-escalation trial, futibatinib demonstrated tolerability, pharmacodynamic activity, and preliminary antitumor activity in heavily pretreated patients with advanced solid tumors.
Brand Name : TAS-120
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 23, 2020
Lead Product(s) : Futibatinib,Olaparib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Taiho Oncology
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Futibatinib,Fluorouracil,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Taiho Oncology to Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020
Details : Futibatinib (TAS-120) plus chemotherapy demonstrated a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 04, 2020
Lead Product(s) : Futibatinib,Fluorouracil,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The interim analysis demonstrated that treatment with the covalently-binding FGFR inhibitor futibatinib may lead to meaningful clinical benefit in patients with refractory iCCA with FGFR2 gene fusions or other rearrangements.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 31, 2020
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?